-

07:20:32 PM

IMMX Stock News

IMMX - Immix Biopharma Inc

03/10/23 7:45 PM

Nasdaq : IMMX

low float

Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today confirms that neither ImmixBio, nor

RHEA-AI

neutral

03/06/23 8:00 AM

Nasdaq : IMMX

clinical triallow float

ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, and its subsidiary Nexcella, Inc.

RHEA-AI

neutral

02/27/23 8:45 AM

Nasdaq : IMMX

fda approvallow float

Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission

Robust enrollment of up to 5 patients per month continues in ongoing Phase 1b/2a next-generation CAR-T NXC-201 clinical trial in relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosis Nexcella on track to present 50-patient cohort multiple myeloma data later this year at a

RHEA-AI

very positive

02/15/23 8:30 AM

Nasdaq : IMMX

clinical triallow float

Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.

Nexcella, Inc. initiates process of bringing NXC-201 to the United States by entering into an agreement with a well-known GMP cell therapy manufacturer that will supply Phase 1b/2 NXC-201 clinical trial material NXC-201 is in development for the treatment of patients with relapsed or refractory

RHEA-AI

very positive

02/09/23 8:00 AM

Nasdaq : IMMX

clinical triallow float

Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting

The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated with NXC-201 (formerly HBI0101), of which 29 received the therapeutic dose of 800 million CAR+T cells as of the data cutoff of October 23, 2022 90% overall response rate (ORR) was observed in 29

RHEA-AI

positive

02/07/23 8:00 AM

Nasdaq : IMMX

clinical triallow float

Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”,

RHEA-AI

neutral

01/13/23 8:00 AM

Nasdaq : IMMX

clinical triallow float

Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

In January 2023, the 17 th new patient was dosed with IMX-110 to date Positive safety data enabled continued dosing of previously enrolled patients Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical data expected to be released on a rolling basis

RHEA-AI

neutral

01/06/23 8:00 AM

Nasdaq : IMMX

clinical triallow float

Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached

NXC-201 treatment continues to demonstrate 100% complete response rate in 6 relapsed/refractory AL amyloidosis patients to-date Clinical data published December 2022 in Clinical Cancer Research demonstrated 100% complete response rate; 100% organ response rate; Duration of Response Not Yet Reached

RHEA-AI

neutral

12/28/22 8:00 AM

Nasdaq : IMMX

low float

Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”,

RHEA-AI

neutral

12/20/22 8:00 AM

Nasdaq : IMMX

clinical triallow float

Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

16 th patient dosed with IMX-110 to date This is the second patient dosed with IMX-110 in December 2022 Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical data expected to be released on a rolling basis beginning in Q1 2023 LOS ANGELES, CA, Dec. 20,

RHEA-AI

neutral

IMMX Data

IndustryResearch and Development in Biotechnology
Websitewww.immixbio.com
Security nameImmix Biopharma Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code2834

About Immix Biopharma Inc

ImmixBioTM is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases. Its proprietary System Multi-Action RegulaTors SMARxT Tissue-SpecificTM Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. ImmixBioTM TME Normalization™ Technology allows its drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. ImmixBioTM has uncovered fundamental biological systems that link oncology and immuno-dysregulated diseases. In addition to oncology, its pipeline includes Tissue-Specific BiologicTM candidates to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.